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Abstract
Background: To assess the clinical outcome of chemoradiotherapy with or without surgery for locally recurrent
rectal cancer (LRRC) and to find useful and significant prognostic factors for a clinical situation.
Methods: Between January 2001 and February 2009, 67 LRRC patients, who entered into concurrent
chemoradiotherapy with or without surgery, were reviewed retrospectively. Of the 67 patients, 45 were treated
with chemoradiotherapy plus surgery, and the remaining 22 were treated with chemoradiotherapy alone. The
mean radiation doses (biologically equivalent dose in 2-Gy fractions) were 54.6 Gy and 66.5 Gy for the
chemoradiotherapy with and without surgery groups, respectively.
Results: The median survival duration of all patients was 59 months. Five-year overall (OS), relapse-free (RFS),
locoregional relapse-free (LRFS), and distant metastasis-free survival (DMFS) were 48.9%, 31.6%, 66.4%, and 40.6%,
respectively. A multivariate analysis demonstrated that the presence of symptoms was an independent prognostic
factor influencing OS, RFS, LRFS, and DMFS. No statistically significant difference was found in OS (p = 0.181), RFS
(p = 0.113), LRFS (p = 0.379), or DMFS (p = 0.335) when comparing clinical outcomes between the
chemoradiotherapy with and without surgery groups.
Conclusions: Chemoradiotherapy with or without surgery could be a potential option for an LRRC cure, and the
symptoms related to LRRC were a significant prognostic factor predicting poor clinical outcome. The
chemoradiotherapy scheme for LRRC patients should be adjusted to the possibility of resectability and risk of local
failure to focus on local control.
Background
Recent advances in preoperative evaluation, treatment
strategies and rectal cancer modalities have lead to bet-
ter survival outcomes for patients with rectal cancer and
a lower incidence of local recurrence [1,2]. Despite such
improvements, 6-10% of patients with primary rectal
cancer still experience intrapelvic local recurrence with
or without distant metastasis [3-5]. These patients show
a poor survival outcome with a nearly zero 5-year survi-
val and 3-12 months of median survival when treated by
only supportive care or palliative treatment [4]. More-
over, troublesome symptoms related to local recurrence
reduce the quality of life during surviving periods.
Recent studies have reported that radical surgery with
microscopic curative resection presents a 48-60% long-
term survival rate in patients surviving at 5 years
[3,4,6-9]. These observations suggest that local control
of LRRC is significantly associated with long-term survi-
val and that the first goal of LRRC treatment should be
local tumor control [5].
However, an aggressive approach with surgery alone
also has severe weaknesses in that curative surgery is
possible for only 20-30% of patients with locally recur-
rent rectal cancer (LRRC), because the intrapelvic space
is too narrow to perform an R0 resection, and previous
treatments, including surgery and radiotherapy, induce
extensive fibrosis [3,4]. Moreover, high post-operative
morbidities, of 30-60% [6-8], and the non-operable state
of some patients should also be considered in the clini-
cal situation. To compensate for the shortage of radical
surgery, chemoradiotherapy (CRT) with adjuvant or
curative intent has a definitive role in improving the
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have demonstrated that multimodal treatment including
CRT results in better clinical outcomes, but the role and
strategies for CRT have not yet been established. Thus,
the purpose of the present study was to assess the clini-
cal outcomes of CRT with or without surgery for
patients with LRRC and to find useful and significant
prognostic factors for the clinical situation.
Methods
Patients
This study was performed in accordance with the guide-
lines of our institutional review board. All patients pro-
vided written informed consent before salvage
treatment.
Between January 2001 and February 2009, 67 patients
with LRRC underwent CRT with or without surgery as
a salvage treatment at the National Cancer Center
(Goyang, Korea). Inclusion criteria were: (1) histologi-
cally confirmed primary rectal adenocarcinoma, (2)
recurrent sites confined to the pelvic cavity, (3) no evi-
dence of distant metastasis, and (4) salvage treatment
with a curative aim.
Patient characteristics are shown in Table 1. The
recurrence-free interval from the initial treatment of the
primary tumor to locoregional recurrence ranged from 3
to 206 months (median, 22 months). Of 67 patients, 45
(67.2%) presented with local recurrence after a sphinc-
ter-saving radical surgery to remove a primary tumor,
17 patients (25.4%) developed recurrence following an
abdominoperineal resection, and five patients (7.5%)
experienced recurrence following local excision. Fifty-
five patients (82.1%) had a history of adjuvant che-
motherapy for a primary tumor, and 23 (34.3%) received
adjuvant radiotherapy for a primary tumor. Symptoms
related to local recurrence were sciatic pain in 17
patients, bowel habit changes in two patients, and a
ureteral obstruction in one patient.
Through biopsy or surgical resection, 45 patients were
confirmed histologically to have developed a local recur-
rence. In 22 patients, radiological evidence, including a
positive positron-emission tomography (PET) scan or
serial radiological examinations that showed progressive
growth of the mass, were considered sufficient evidence
to diagnose a local recurrence [10,11]. All patients were
evaluated by digital rectal examination, a complete
blood count, a liver function test, carcinoembryonic
antigen (CEA) level, computed tomography (CT) of the
chest and abdomino-pelvis, whole body PET, and mag-
netic resonance imaging (MRI) of the pelvis.
Treatment
Following the diagnosis of a locoregional recurrence, a
surgeon, a medical oncologist, and a radiation oncologist
reviewed the results of the diagnostic work-up to deter-
mine which treatment modality would be best suited for
each patient. Considered unsuitable for curative surgery,
22 patients among 67 patients received definitive CRT
without surgery. The other 45 underwent resection of a
locally recurrent lesion with curative intent and preo-
perative (n = 3) or postoperative CRT (n = 42). Most
adjuvant RT approaches consisted of post-operative,
rather than pre-operative, as following reasons. (1) If a
diagnosis is uncertain, histological confirm was possible
through surgery. (2) If a patient has limitations for RT,
Table 1 Patient and treatment characteristics
Characteristics Value (%)
Median age, years (range) 57 (30-84)
Gender
Male 40 (59.7)
Female 27 (40.3)
Stage at initial diagnosis
ypStage 0 3 (4.2)
pStage I/ypStage I 5 (7.0)/1 (1.4)
pStage II/ypStage II 14 (19.7)/3 (4.2)
pStage III/ypStage III 21 (29.6)/8 (11.3)
pStage IV/ypStage IV 6 (8.5)/1 (1.4)
pT1-2Nx 5 (7.0)
Recurrence history
0 51 (76.1)
1 16 (23.9)
Symptoms at recurrence
Yes 20 (29.9)
No 47 (70.1)
Recurrent site
Central 21 (31.3)
Lateral 30 (44.8)
Posterior 16 (23.9)
Pretreatment CEA
Normal (≤ 5 ng/mL) 37 (55.2)
High (> 5 ng/mL) 30 (44.8)
Salvage treatment
Surgery + CRT 45 (67.2)
CRT alone 22 (32.8)
Chemotherapy regimen
Fluoropyrimidine-alone 35 (52.2)
Irinotecan or Oxaliplatin-based 31 (46.3)
No 1 (1.5)
Radicality of resection
R0 19 (28.4)
R1 24 (35.8)
R2 2 (4.0)
No surgery 22 (32.8)
Median radiation dose, Gy (range) 57.2 (44.3-74.4)
Values in parentheses are percentages unless indicated otherwise. CRT,
chemoradiotherapy; R0, microscopically radical; R1, microscopically irradical;
R2, macroscopically irradical; Gy, Gray; CEA, carcinoembryonic antigen.
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recurrence site, we performed omental flap transposition
[12]. It functioned as spacer to increase a distance
between small bowel and RT target area. (3) If RT target
area and rectum are too close, we could perform protec-
tive colostomy for the prevention of RT-induced procti-
tis. (4) In some cases, preferences of doctor and patient
were cause of such practice.
Radiotherapy was administered using three-dimen-
sional conformal radiation (n = 60), proton beam ther-
apy (n = 4), or helical tomotherapy (n = 3). All patients
underwent a CT simulation in the treatment position,
which was generally prone. The gross tumor volume,
consisting of all detectable tumors, was determined
from the CT, PET, and MRI data. The clinical target
volume covered the gross tumor volume, tumor bed,
and other suspicious microscopic lesions. The initial
planning target volume included the clinical target
volume plus a 10-20 mm margin. Organs at risk were
also delineated, including the spinal cord, bladder, both
kidneys, and the small bowel.
The radiation dose was 45-72 Gy, with fraction sizes
of 1.8-3.0 Gy (biologically equivalent dose in 2-Gy frac-
tions [BED2Gy] using a linear quadratic model, and the
a/b; ratio was 10 for acute effects on normal tissues and
tumors: 44.3-74.4 BED2Gy), and the median dose was
57.2 BED2Gy. The dose-fractionation schedules were as
follows: 1.8 Gy/fraction in 60 patients, 2.4 Gy/fraction in
four patients, 2.7 Gy/fraction in one patient, 2.8 Gy/frac-
tion in one patient, and a 3 Gy/fraction in one patient.
The radiation dose was adjusted according to the status
of the residual tumor, radiation history, and proximity
to the small bowel.
Most patients underwent concurrent chemotherapy
with radiation, consisting of a fluoropyrimidine (n = 35),
irinotecan, or oxaliplatin-based regimens (n =3 1 ) .O n l y
one patient could not receive chemotherapy, because of
hepatitis. Maintenance chemotherapy after concurrent
CRT was applied to 88.1% of patients (n =5 9 ) ,w h i c h
consisted of a fluoropyrimidine regimen (n = 23) and an
irinotecan or oxaliplatin-based regimen (n = 36). The
remaining eight patients did not undergo maintenance
chemotherapy because of patient refusal (n = 6) or poor
performance status (n = 2).
Evaluation
After salvage treatment, follow-up was performed every
3 months for the first 2 post-treatment years and every
6 months thereafter. Follow-up evaluations included a
physical examination, digital rectal examination, com-
plete blood count, liver function test, and serum CEA
level at each visit. Chest radiography and CT scanning
of the abdomen and pelvis were performed every 6
months after salvage treatment. Relapse after salvage
treatment was confirmed pathologically by direct biopsy
or cytology, and/or radiographical evidence. Locoregio-
nal failure was defined as a new lesion or disease pro-
gression within the pelvic cavity, and distant failure as
any recurrence outside the pelvic cavity.
Statistical Analyses
Overall survival (OS), relapse-free survival (RFS), locore-
gional relapse-free survival (LRFS), and distant metasta-
sis-free survival (DMFS) were calculated as the interval
from the first date of salvage treatment to the date of
death, any relapse detection, locoregional relapse detec-
tion, or distant metastasis detection, respectively.
Survival curves were generated by the Kaplan-Meier
method, and a univariate survival comparison was per-
formed using the log-rank test. Multivariate analyses
were conducted with the Cox proportional hazards
model and the backward stepwise selection procedure.
The chi-squared, Fisher’se x a c t ,a n dt-tests were per-
formed to compare various parameters between different
treatment groups. A p-value of < 0.05 was considered
to indicate statistical significance.
Results
Survival and pattern of failure
The median follow-up time for living patients was 41
months (range, 16-108). The median OS of all patients
was 59 months. Median RFS, LRFS, and DMFS were 18,
not reached, and 23 months, respectively. Five-year OS,
RFS, LRFS, and DMFS were 48.9%, 31.6%, 66.4%, and
40.6%, respectively. A relapse after salvage treatment
occurred in 41 (61.2%) patients during the follow-up
period, and locoregional failure was detected in six
patients (9.0%), distant metastasis in 30 patients (44.8%),
and both failures in five patients (7.5%). During follow-
up period, severe G-I complication over Grade III, asso-
ciated with CRT, did not occur.
Analysis of prognostic factors
The univariate analysis of the effect of prognostic factors
on clinical outcome is shown in Table 2. The presence
of symptoms was a significant prognostic factor corre-
lated with poor OS (p = 0.025), RFS (p = 0.007), LRFS
(p = 0.003), and DMFS (p = 0.047). In contrast, age,
gender, type of primary surgery, recurrence-free interval,
recurrence history, recurrence site, pre-treatment CEA
serum level, salvage treatment, chemotherapy regimen,
resection margin, and radiation dose had no statistically
significant effect on OS, RFS, LFS, or DMFS. In the
multivariate analysis, the presence of symptoms was an
independent prognostic factor predicting poor OS (p =
0.025; hazard ratio [HR], 3.46; 95% confidence interval
[CI], 1.17-10.22), RFS (p = 0.017; HR, 3.04; 95% CI,
1.22-7.59), LRFS (p = 0.005; HR, 3.60; 95% CI, 1.48-
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7.89).
Comparison between CRT with and without surgery
No statistically significant difference was found in OS (p
= 0.181), RFS (p = 0.113), LRFS (p = 0.379), or DMFS
(p = 0.458) when clinical outcomes were compared
between the CRT with surgery and definitive CRT with-
out surgery groups. Figure 1 shows the OS and RFS
curves for each group. The prognostic factors, as
described above, were stratified by the two groups and
are shown in Table 3. Significantly more patients with
symptoms and an abnormal CEA level (> 5 ng/mL)
received definitive CRT without surgery (p = 0.014,
0.009, respectively). The mean radiation dose was 54.6
BED2Gy i nt h eC R Tw i t hs u r g e r yg r o u p ,a n d6 6 . 5
BED2Gy in the definitive CRT without surgery group (p
< 0.001). In addition, post-operative RT dose was also
different according to margins status. Patients with a
positive resection margin received the higher radiation
dose (mean dose, 57.5 BED2Gy) than patients with a
negative resection margin (mean dose, 50.6 BED2Gy).
Discussion
This study assessed whether CRT with or without sur-
gery was effective in patients with LRRC and identified
Table 2 Univariate analysis of factors affecting clinical outcome
5y OS p† 5y RFS p† 5y LRFS p† 5y DMFS p†
Age (years)
< 60 50.5 .653 27.6 .547 57.6 .084
≥60 47.9 36.2 75.9
Gender
Male 55.6 .381 34.8 .340 73.7 .141 42.3 .811
Female 34.9 27.7 55.7 38.1
Recurrence-free interval (months)
<24 46.4 .675 33.2 .473 59.8 .248 40.6 .663
≥24 50.7 26.9 72.9 38.5
Previous recurrence history
0 51.2 .417 36.4 .061 66.9 .834 43.0 .420
1 38.8 16.7 65.2 33.0
Symptoms at recurrence
Yes 26.3 .025 20.0 .007 40.0 .003 25.8 .047
No 58.4 38.3 76.2 47.2
Recurrence site
Central 56.0 .494 43.5 .429 67.7 .918 54.2 .305
Lateral 44.8 26.0 69.1 31.5
posterior 36.4 35.3 63.5 36.2
Pretreatment CEA (ng/mL)
≤5 45.7 .882 41.8 .071 72.1 .154 49.2 .458
>5 52.8 21.8 59.1 33.8
Salvage Treatment
Surgery + CRT 52.8 .181 35.2 .113 71.0 .379 43.6 .335
CRT alone 40.6 24.5 55.9 34.6
Chemotherapy regimen
Fluoropyrimidines-alone 47.3 .910 36.7 .572 67.2 .720 42.9 .562
Irinotecan or Oxaliplatin -based 41.0 22.0 64.7 33.8
Resection§
R0 60.4 .994 35.1 .956 77.7 .529 37.6 .919
R1 or R2 42.9 34.3 65.6 46.8
Radiation dose (BED2Gy)
<60 46.9 .607 32.3 .281 78.2 .065 41.0 .694
≥60 48.3 29.2 52.9 39.2
*values are percentages of patients; †log rank test. OS, overall survival; § Among 45 patients undergoing surgical resection; RFS, recurrence-free survival; LRFS,
locoregional relapse free survival; DMFS, distant metastasis-free survival; CRT, chemoradiotherapy; R0, microscopically radical; R1, microscopically irradical; R2,
macroscopically irradical; BED2Gy, biologically equivalent dose in 2-Gy fractions using a linear quadratic model, and the a/b ratio was 10 for acute effects on
normal tissues and tumors. CEA, carcinoembryonic antigen.
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year OS of 48.9% and a LRFS of 66.4% was achieved;
this outcome was better than previous multimodal treat-
ment reports (5-yr OS of 25-36%, LRFS of 40-50%).
However, DMFS was similar to the results of previous
studies and was approximately 40-50% [6-8,13-15].
When evaluating prognostic factors, symptoms related
to LRRC have a significant effect on OS, RFS, LRFS, and
A
B
Figure 1 Overall survival (a) and relapse-free survival (b) between the chemoradiotherapy with surgery and without surgery groups.
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the clinical outcomes for many kinds of cancer and
could be considered a potential prognostic factor. In
other studies, symptoms related to LRRC have been
reported as significant prognostic factors for a poor out-
come [6,7,13] and such patients are considered a low
possibility for radical resection [13]. Hydronephrosis
presenting in two patients indicated a lower chance for
obtaining a negative resection margin [16]. LRRC symp-
t o m sa r eau s e f u la n dr e a d i l ya s s e s s a b l ep r o g n o s t i cf a c -
tor in the clinical setting.
Another strength of the present study was that CRT
was tailored to the individual risk of a residual tumor
and the potential risk of a complication after an attempt
at curative resection. The patients in the LRRC group
were actually heterogeneous when considering resect-
ability, the strongest factor affecting clinical outcome.
Tumor location and the degree of local invasion affect
resectability, and the posterior and lateral location, par-
ticularly including a sacral, ureteral, or iliac vessel inva-
sion, are almost unresectable and cause marked
postoperative disability [10,17]. Many studies on multi-
modal LRRC treatment have attempted preoperative
CRT to solve the problem of low resectability
[6-9,13,18-20], and one of those studies demonstrated
significantly increased resectability [6]. However, resect-
ability improved by preoperative CRT was still insuffi-
cient, at 30-60% [6-8,13,15,18,21]. The remaining 40-
70% of patients with incompletely resected LRRC
showed disappointing local control (30% 3-year LRFS),
and this insufficient local control lead to a poor survival
outcome of 10-16% for the 5-year OS [6,8]. Moreover,
the pre-operative CRT radiation dose was a uniform low
dose of 30-50 Gy, but did not consider the risk of an
unresectable or residual tumor. When local control is
the prime goal of LRRC treatment, the radiation dose or
CRT plan should be determined based on such risks for
local failure and complication.
All patients, except three who underwent preoperative
CRT followed by radical resection, received CRT with
an adjusted postoperative or definitive radiation dose,
based on the risk for local failure and complication. In
the preoperative evaluation, poor surgical candidates
who were definitively unresectable or medically inoper-
able underwent definitive CRT with a high radiation
dose (mean dose, 66.5 BED2Gy). In patients with a posi-
tive resection margin, the post-operative radiation dose
(mean dose, 57.5 BED2Gy) was also higher than in
patients with a negative resection margin (mean dose,
50.6 BED2Gy). Some studies have demonstrated that a
higher radiation dose for patients with LRRC is corre-
lated with better clinical outcome [6,20]. Fifteen patients
underwent omental flap transposition as a spacer, as
proposed by Kim et al. [12] and seven patients received
proton beam or helical tomotherapy to safely deliver a
high dose of radiation to recurrent sites in patients who
had previously undergone radiation and whose small
bowel is very close to the target area. The radiation plan
also focused on risky areas for local failure, referring to
operative findings and pathological reports. As a result,
this study showed improved local control, leading to
improved OS. Moreover, patients with a positive
Table 3 Patient characteristics between the surgery plus
chemoradiation and chemoradiation alone groups
Characteristic Surgery +
chemoradiation
(n = 45)
chemoradiation
(n = 22)
P
Mean age, years 56.7 ± 11.5 60.0 ± 13.4 0.377§
Gender
Male 25 15 0.322†
Female 20 7
Recurrence-free
interval, months
35.3 30.0 0.521§
Chemotherapy history
Yes 35 20 0.310‡
No 10 2
Radiation history
Yes 14 6 0.747†
No 31 16
Recurrence history
0 35 16 0.649†
11 0 6
Symptoms at
recurrence
Yes 9 11 0.014†
no 36 11
Recurrence site
Central 16 5 0.440†
Lateral 20 10
posterior 9 7
Pretreatment CEA (ng/
mL)
≤5 30 7 0.009†
>5 15 15
Chemotherapy
regimen
Fluoropyrimidines
alone
21 13 0.249†
Irinotecan or
oxaliplatin-based
24 8
Radiation dose
(BED2Gy)
<60 34 1 <0.001†
≥60 11 21
Mean radiation dose,
BED2Gy
54.6 ± 5.5 66.5 ± 6.2 <0.001§
†chi-squared test; ‡ Fisher exact test; § t-test; BED2Gy, biologically equivalent
dose in 2-Gy fractions using a linear quadratic model, CEA, carcinoembryonic
antigen; and the a/b; ratio was 10 for acute effects on normal tissues and
tumors.
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(5-year OS, 42.9%) than other studies [6,7,13]. This
study showed that the purpose of CRT should not be
just adjuvant, aimed at increasing resectability, but an
aggressive curative local control, similar to surgery. Such
a treatment plan could result in an increased cure rate
with long-term survival.
The present study also showed that definitive CRT
with a high radiation dose (mean dose, 66.5 BED2Gy)
may be a potentially curative option for long-term survi-
val (5-year OS, 48.9%). The actuarial 5-year OS, RFS,
LRFS, and DMFS for definitive CRT was not signifi-
cantly different than CRT with surgery. However, med-
ian OS, RFS, LRFS, and DMFS for definitive CRT
tended to be slightly inferior to the surgery group, but
this difference was not statistically significant. Patients
with an abnormal CEA level or the presence of symp-
toms occurred more in the definitive CRT group, and
this may have affected the outcome of the definitive
CRT group. Symptoms were a significant prognostic fac-
tor in the present study and CEA level has been
reported as a significant prognostic factor in some pre-
vious studies [22,23]. Although definitive CRT cannot
substitute for radical surgery, it can be an option aimed
at a cure with long-term survival for a fair number of
patients with an inoperable medical condition or an
unresectable lesion.
The present study has some limitations. First, in con-
trast to other studies, the radicality of resection was not
a significant prognostic factor predicting survival out-
come or tumor control. It might be related with low sta-
tistical power due to small sample size (n =6 7 ) .I n
addition, the reason could be also that radiation dose
was increased according to residual tumor status. Such
a difference in the radiation dose appeared to dilute the
effect of surgical radicality. Another reason could be
that a relatively small proportion of R2 resections (4%)
of the CRT with surgery might induce improvement in
the group with positive resection margin. Patients with
expected unresectability from the radiological evaluation
were recommended for definitive CRT without surgery,
so a R2 resection might have been rarer than in other
studies. In that R2 resection have more effect on an
unfavorable clinical outcome than R1 resection [24], the
effect of radicality might fail to get the statistical signifi-
cance. Second, we could observe tendency in the survi-
val curves that the CRT with surgery got the slightly
more favorable outcome than the definitive CRT group,
but it failed to get a statistical significance. This could
be resulted from the effects of a small sample size, sur-
gical morbidities, and the differences of radiation dose.
This study showed the possibility of a definitive CRT for
cure, but further study with a larger sample size is
needed for a definitive conclusion about the comparison
between the two groups. Third, we had a heterogeneous
population undergoing different CRT approaches and
chemotherapy regimens. Accordingly, further larger
scale and prospective studies with additional long-term
follow-up are needed to compare different CRT
approaches definitively.
Conclusions
Our study demonstrated that LRRC has the potential to
be cured with CRT with or without surgery, and the
symptoms related to LRRC are a significant prognostic
factor predicting poor clinical outcome. The CRT
approach should focus on local control; thus, individua-
lized CRT strategies are recommended, based on the
possibility of resectability and risk of local failure. Thus,
CRT with an adjusted radiation dose is a potential cura-
tive option for LRRC, including definitive CRT without
surgery.
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